PMID- 17458859
OWN - NLM
STAT- MEDLINE
DCOM- 20070911
LR  - 20171116
IS  - 0014-2980 (Print)
IS  - 0014-2980 (Linking)
VI  - 37
IP  - 6
DP  - 2007 Jun
TI  - Erythropoietin enhances immune responses in mice.
PG  - 1584-93
AB  - Erythropoietin (Epo) is the main erythropoietic hormone. Recombinant human Epo 
      (rHuEpo) is thus used in clinical practice for the treatment of anemia. 
      Accumulating data reveals that Epo exerts pleiotropic activities. We have 
      previously shown an anti-neoplastic activity of Epo in murine multiple myeloma 
      (MM) models, and in MM patients. Our findings that this anti-neoplastic effect 
      operates via CD8+ T lymphocytes led us to hypothesize that Epo possesses a wider 
      range of immunomodulatory functions. Here we demonstrate the effect of Epo on B 
      lymphocyte responses, focusing on three experimental models: (i) tumor-bearing 
      mice, (5T2 MM mouse); (ii) antigen-injected healthy mice; and (iii) 
      antigen-injected transgenic mice (tg6), overexpressing human Epo. In the MM 
      model, despite bone marrow dysfunction, Epo-treated mice retained higher levels 
      of endogenous polyclonal immunoglobulins, compared to their untreated controls. 
      In both Epo-treated wild type and tg6 mice, Epo effect was manifested in the 
      higher levels of splenocyte proliferative response induced in vitro by 
      lipopolysaccharide. Furthermore, these mice had increased in vivo production of 
      anti-dinitrophenyl (DNP) antibodies following immunization with DNP-keyhole 
      limpet hemocyanin. Epo-treated mice showed an enhanced immune response also to 
      the clinically relevant hepatitis B surface antigen. These findings suggest a 
      potential novel use of rHuEpo as an immunomodulator.
FAU - Katz, Odelia
AU  - Katz O
AD  - Department of Cell and Developmental Biology, Sackler Faculty of Medicine, 
      Tel-Aviv University, Tel-Aviv, Israel.
FAU - Gil, Lidor
AU  - Gil L
FAU - Lifshitz, Lilach
AU  - Lifshitz L
FAU - Prutchi-Sagiv, Sara
AU  - Prutchi-Sagiv S
FAU - Gassmann, Max
AU  - Gassmann M
FAU - Mittelman, Moshe
AU  - Mittelman M
FAU - Neumann, Drorit
AU  - Neumann D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Immunol
JT  - European journal of immunology
JID - 1273201
RN  - 0 (2,4-dinitrophenyl keyhole limpet hemocyanin)
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD3 Complex)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin gamma-Chains)
RN  - 0 (Immunoglobulin kappa-Chains)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Recombinant Proteins)
RN  - 11096-26-7 (Erythropoietin)
RN  - 9013-72-3 (Hemocyanins)
SB  - IM
CIN - Eur J Immunol. 2007 Jun;37(6):1427-30. PMID: 17506033
MH  - Adjuvants, Immunologic/genetics/*pharmacology
MH  - Animals
MH  - Antibodies, Monoclonal/immunology/pharmacology
MH  - Antibody Formation/*drug effects/immunology
MH  - B-Lymphocytes/cytology/drug effects/immunology
MH  - CD3 Complex/immunology
MH  - Cell Proliferation/drug effects
MH  - Erythropoietin/genetics/*pharmacology/therapeutic use
MH  - Female
MH  - Hemocyanins/immunology
MH  - Hepatitis B Surface Antigens/immunology
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Immunoglobulin gamma-Chains/blood
MH  - Immunoglobulin kappa-Chains/blood
MH  - Lipopolysaccharides/pharmacology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Multiple Myeloma/blood/drug therapy
MH  - Recombinant Proteins/pharmacology/therapeutic use
MH  - Survival Analysis
MH  - T-Lymphocytes/cytology/drug effects/immunology
MH  - Vaccination
EDAT- 2007/04/27 09:00
MHDA- 2007/09/12 09:00
CRDT- 2007/04/27 09:00
PHST- 2007/04/27 09:00 [pubmed]
PHST- 2007/09/12 09:00 [medline]
PHST- 2007/04/27 09:00 [entrez]
AID - 10.1002/eji.200637025 [doi]
PST - ppublish
SO  - Eur J Immunol. 2007 Jun;37(6):1584-93. doi: 10.1002/eji.200637025.